Lightrock Netherlands B.V. Acquires 14,750 Shares of Globus Medical, Inc. $GMED

Lightrock Netherlands B.V. raised its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 6.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 251,900 shares of the medical device company’s stock after acquiring an additional 14,750 shares during the quarter. Globus Medical makes up about 3.2% of Lightrock Netherlands B.V.’s portfolio, making the stock its 13th biggest position. Lightrock Netherlands B.V.’s holdings in Globus Medical were worth $14,426,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in GMED. EverSource Wealth Advisors LLC boosted its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Globus Medical in the 2nd quarter valued at about $28,000. First Horizon Corp purchased a new position in shares of Globus Medical in the 3rd quarter worth approximately $31,000. CENTRAL TRUST Co bought a new position in shares of Globus Medical during the 2nd quarter worth approximately $39,000. Finally, Headlands Technologies LLC lifted its position in Globus Medical by 485.4% during the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after acquiring an additional 631 shares during the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Kelly Huller sold 7,500 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $90.00, for a total value of $675,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $86.00, for a total transaction of $2,150,000.00. Following the transaction, the director directly owned 516,275 shares of the company’s stock, valued at approximately $44,399,650. This trade represents a 4.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 91,636 shares of company stock worth $7,984,583. Company insiders own 18.51% of the company’s stock.

Globus Medical Stock Performance

Shares of GMED stock opened at $92.55 on Friday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The firm has a market capitalization of $12.39 billion, a PE ratio of 29.86, a P/E/G ratio of 1.37 and a beta of 1.06. The stock’s 50-day simple moving average is $89.30 and its 200-day simple moving average is $70.36.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, November 6th. The medical device company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The firm had revenue of $769.05 million for the quarter, compared to analyst estimates of $734.58 million. During the same quarter in the prior year, the firm earned $0.83 earnings per share. Globus Medical’s revenue for the quarter was up 22.9% on a year-over-year basis. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. Sell-side analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GMED. Bank of America raised Globus Medical from a “neutral” rating to a “buy” rating and upped their price target for the stock from $65.00 to $91.00 in a research report on Friday, November 7th. Barclays increased their price target on Globus Medical from $106.00 to $114.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Royal Bank Of Canada boosted their price target on Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Citigroup restated a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Globus Medical in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.78.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.